INKT

SEC source: 0000950170-23-046775 · ownership.xml · nonDerivative · entry 1

Baldoni John · CIK 0001851248 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 41,193

F1 · price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Common Stock for each RSU. The RSUs were received in lieu of cash retainers for board and committee compensation. The RSUs will vest one month from the grant date.

F2 · balance_after: In Table 1 of the Form 4 filed on June 2, 2023, the amount of securities acquired and price (column 4) and amount of securities beneficially owned following reported transaction (column 5) were erroneously reported. On June 1, 2023, 7,987 RSUs were acquired at a price of $1.80 each, resulting in a total amount of securities beneficially owned following the reported transaction of 31,347 instead of 31,528 as erroneously reported.

SEC source: 0000950170-23-046777 · ownership.xml · nonDerivative · entry 1

Behner Peter · CIK 0001851420 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 44,058

F1 · price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Common Stock for each RSU. The RSUs were received in lieu of cash retainers for board and committee compensation. The RSUs will vest one month from the grant date.

F2 · balance_after: In Table 1 of the Form 4 filed on June 2, 2023, the amount of securities acquired and price (column 4) and amount of securities beneficially owned following reported transaction (column 5) were erroneously reported. On June 1, 2023, 8,542 RSUs were acquired at a price of $1.80 each, resulting in a total amount of securities beneficially owned following the reported transaction of 33,527 instead of 33,721 as erroneously reported.

SEC source: 0000950170-23-046773 · ownership.xml · nonDerivative · entry 1

WIINBERG ULF · CIK 0001187314 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 60,119

F1 · price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Common Stock for each RSU. The RSUs were received in lieu of cash retainers for board and committee compensation. The RSUs will vest one month from the grant date.

F2 · balance_after: In Table 1 of the Form 4 filed on June 2, 2023, the amount of securities acquired and price (column 4) and amount of securities beneficially owned following reported transaction (column 5) were erroneously reported. On June 1, 2023, 7,778 RSUs were acquired at a price of $1.80 each, resulting in a total amount of securities beneficially owned following the reported transaction of 50,529 instead of 50,706 as erroneously reported.

SEC source: 0000950170-23-046776 · ownership.xml · nonDerivative · entry 1

Corvese Brian · CIK 0001393207 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 329,523

F1 · price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Common Stock for each RSU. The RSUs were received in lieu of cash retainers for board and committee compensation. The RSUs will vest one month from the grant date.

F2 · balance_after: In Table 1 of the Form 4 filed on June 2, 2023, the amount of securities acquired and price (column 4) and amount of securities beneficially owned following reported transaction (column 5) were erroneously reported. On June 1, 2023, 9,931 RSUs were acquired at a price of $1.80 each, resulting in a total amount of securities beneficially owned following the reported transaction of 317,279 instead of 317,505 as erroneously reported.

SEC source: 0000950170-23-046774 · ownership.xml · nonDerivative · entry 1

Ryan Barbara · CIK 0001827169 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,864

F1 · price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Common Stock for each RSU. The RSUs were received in lieu of cash retainers for board and committee compensation. The RSUs will vest one month from the grant date.

F2 · balance_after: In Table 1 of the Form 4 filed on June 2, 2023, the amount of securities acquired and price (column 4) and amount of securities beneficially owned following reported transaction (column 5) were erroneously reported. On June 1, 2023, 9,862 RSUs were acquired at a price of $1.80 each, resulting in a total amount of securities beneficially owned following the reported transaction of 38,706 instead of 38,930 as erroneously reported.

SEC source: 0000950170-23-045816 · ownership.xml · nonDerivative · entry 1

AGENUS INC · CIK 0001098972 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,734,887

F1 · price: Open market purchases reported on this line occurred at a weighted average price of $1.5168 (range of $1.50 to $1.52).

F2 · price: Agenus Inc. undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares purchased at each separate price.

SEC source: 0000899243-23-018546 · doc4.xml · nonDerivative · entry 2

AGENUS INC · CIK 0001098972 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,705,209

F2 · price: Agenus Inc. undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares purchased at each separate price.

F3 · price: Open market purchases reported on this line occurred at a weighted average price of $1.4499 (range of $1.44 to $1.45).

SEC source: 0000899243-23-018546 · doc4.xml · nonDerivative · entry 1

AGENUS INC · CIK 0001098972 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,692,401

F1 · price: Open market purchases reported on this line occurred at a weighted average price of $1.5443 (range of $1.52 to $1.55).

F2 · price: Agenus Inc. undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares purchased at each separate price.

SEC source: 0000899243-23-015839 · doc4.xml · derivative · entry 1

Baldoni John · CIK 0001851248 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,500

Underlying: Common Stock · 22,500 shares

Expires 2033-06-14

F1 · derivative.exercise_date: The option vests in full on the one-year anniversary of the date of grant, provided that the Reporting Person continues to serve on the Issuer's Board of Directors through such date.

SEC source: 0000899243-23-015852 · doc4.xml · derivative · entry 1

Behner Peter · CIK 0001851420 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,500

Underlying: Common Stock · 22,500 shares

Expires 2033-06-14

F1 · derivative.exercise_date: The option vests in full on the one-year anniversary of the date of grant, provided that the Reporting Person continues to serve on the Issuer's Board of Directors through such date.

SEC source: 0000899243-23-015837 · doc4.xml · derivative · entry 1

WIINBERG ULF · CIK 0001187314 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,500

Underlying: Common Stock · 22,500 shares

Expires 2033-06-14

F1 · derivative.exercise_date: The option vests in full on the one-year anniversary of the date of grant, provided that the Reporting Person continues to serve on the Issuer's Board of Directors through such date.

SEC source: 0000899243-23-015843 · doc4.xml · derivative · entry 1

Corvese Brian · CIK 0001393207 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 37,500

Underlying: Common Stock · 37,500 shares

Expires 2033-06-14

F1 · derivative.exercise_date: The option vests in full on the one-year anniversary of the date of grant, provided that the Reporting Person continues to serve on the Issuer's Board of Directors through such date.

SEC source: 0000899243-23-015849 · doc4.xml · derivative · entry 1

Ryan Barbara · CIK 0001827169 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 37,500

Underlying: Common Stock · 37,500 shares

Expires 2033-06-14

F1 · derivative.exercise_date: The option vests in full on the one-year anniversary of the date of grant, provided that the Reporting Person continues to serve on the Issuer's Board of Directors through such date.

SEC source: 0000899243-23-014409 · doc4.xml · nonDerivative · entry 1

Baldoni John · CIK 0001851248 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 31,528

F1 · price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Common Stock for each RSU. The RSUs were received in lieu of cash retainers for board and committee compensation. The RSUs will vest one month from the grant date.

SEC source: 0000899243-23-014412 · doc4.xml · nonDerivative · entry 1

Behner Peter · CIK 0001851420 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,721

F1 · price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Common Stock for each RSU. The RSUs were received in lieu of cash retainers for board and committee compensation. The RSUs will vest one month from the grant date.

SEC source: 0000899243-23-014410 · doc4.xml · nonDerivative · entry 1

WIINBERG ULF · CIK 0001187314 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,706

F1 · price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Common Stock for each RSU. The RSUs were received in lieu of cash retainers for board and committee compensation. The RSUs will vest one month from the grant date.

SEC source: 0000899243-23-014415 · doc4.xml · nonDerivative · entry 1

Corvese Brian · CIK 0001393207 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 317,505

F1 · price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Common Stock for each RSU. The RSUs were received in lieu of cash retainers for board and committee compensation. The RSUs will vest one month from the grant date.

SEC source: 0000899243-23-014414 · doc4.xml · nonDerivative · entry 1

Ryan Barbara · CIK 0001827169 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 38,930

F1 · price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Common Stock for each RSU. The RSUs were received in lieu of cash retainers for board and committee compensation. The RSUs will vest one month from the grant date.

SEC source: 0000950170-23-021854 · ownership.xml · nonDerivative · entry 2

AGENUS INC · CIK 0001098972 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,640,473

F2 · price: Agenus Inc. undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares purchased at each separate price.

F3 · price: Open market purchases reported on this line occurred at a weighted average price of $1.4275 (range of $1.38 to $1.495).

SEC source: 0000950170-23-021854 · ownership.xml · nonDerivative · entry 1

AGENUS INC · CIK 0001098972 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,617,112

F1 · price: Open market purchases reported on this line occurred at a weighted average price of $1.509 (range of $1.47 to $1.54).

F2 · price: Agenus Inc. undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares purchased at each separate price.

SEC source: 0000950170-23-018413 · ownership.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,866,400

F1 · kind: On May 5, 2023, Garo Armen sold 100,000 shares of Mink Therapeutics, Inc. common stock to Agenus Inc. at the acquisition price he paid on May 2, 2023. The acquisition price represents a 40% discount to the market price as of today's market close. Garo Armen did not recognize a profit upon the sale of the shares.

SEC source: 0000950170-23-018401 · ownership.xml · nonDerivative · entry 4

AGENUS INC · CIK 0001098972 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,595,047

SEC source: 0000950170-23-018401 · ownership.xml · nonDerivative · entry 3

AGENUS INC · CIK 0001098972 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,594,847

F4 · kind: On May 5, 2023, Agenus purchased 100,000 shares of MiNk Therapeutics, Inc. common stock from Garo Armen, Agenus's Chairman and CEO, at the same price he paid to acquire the shares on May 2, 2023. The acquisition price represents a 40% discount to the market price as of today's market close.

SEC source: 0000950170-23-018401 · ownership.xml · nonDerivative · entry 2

AGENUS INC · CIK 0001098972 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,494,847

F2 · price: Agenus Inc. undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares purchased at each separate price.

F3 · price: Open market purchases reported on this line occurred at a weighted average price of $1.0789 (range of $1.20 to $1.25).

SEC source: 0000950170-23-018401 · ownership.xml · nonDerivative · entry 1

AGENUS INC · CIK 0001098972 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,473,374

F1 · price: Open market purchases reported on this line occurred at a weighted average price of $1.0789 (range of $0.9144 to $1.20).

F2 · price: Agenus Inc. undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares purchased at each separate price.

SEC source: 0000950170-23-018042 · ownership.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,978,010

SEC source: 0000899243-23-012119 · doc4.xml · nonDerivative · entry 1

AGENUS INC · CIK 0001098972 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,344,685

F1 · kind: On May 1, 2023, Agenus Inc. ("Agenus") paid its previously announced pro rata stock dividend (the "Dividend") consisting of an aggregate of 4,988,081 shares of common stock of MiNK Therapeutics, Inc. ("MiNK") held by Agenus (the "Dividend Shares") to record holders of Agenus's common stock as of April 17, 2023 (the "Record Date"). Agenus distributed 0.0146 of a share of MiNK's common stock for each share of Agenus's common stock outstanding as of the close of business on the Record Date. No fractional shares were issued in connection with the Dividend and the equityholders of Agenus who were entitled to receive fractional shares of the Dividend Shares received cash (without interest) in lieu of such fractional shares and 192 MiNK shares owned by Agenus that represented the aggregate number of fractional shares that would have been distributed were retired.

SEC source: 0000950170-23-024556 · ownership.xml · nonDerivative · entry 1

AGENUS INC · CIK 0001098972 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,326,369

F1 · kind: On May 1, 2023, Agenus Inc. ("Agenus") paid its previously announced pro rata stock dividend (the "Dividend") consisting of an aggregate of 5,006,397 shares of common stock of MiNK Therapeutics, Inc. ("MiNK") held by Agenus (the "Dividend Shares") to record holders of Agenus's common stock as of April 17, 2023 (the "Record Date"). Agenus distributed 0.0146 of a share of MiNK's common stock for each share of Agenus's common stock outstanding as of the close of business on the Record Date. No fractional shares were issued in connection with the Dividend and the equityholders of Agenus who were entitled to receive fractional shares of the Dividend Stock received cash (without interest) in lieu of such fractional shares.

F2 · kind: The Form 4 filed by Agenus on May 3, 2023 inadvertently underreported the number of Dividend Shares distributed to record holders of Agenus's common stock as of the Record Date by 18,316 shares.

SEC source: 0000899243-23-006915 · doc4.xml · nonDerivative · entry 1

Baldoni John · CIK 0001851248 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,360

F1 · price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Common Stock for each RSU. The RSUs were received in lieu of cash retainers for board and committee compensation. The RSUs will vest one month from the grant date.

SEC source: 0000899243-23-006912 · doc4.xml · nonDerivative · entry 1

Behner Peter · CIK 0001851420 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,985

F1 · price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Common Stock for each RSU. The RSUs were received in lieu of cash retainers for board and committee compensation. The RSUs will vest one month from the grant date.

SEC source: 0000899243-23-006928 · doc4.xml · nonDerivative · entry 1

WIINBERG ULF · CIK 0001187314 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 42,751

F1 · price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Common Stock for each RSU. The RSUs were received in lieu of cash retainers for board and committee compensation. The RSUs will vest one month from the grant date.

SEC source: 0000899243-23-006922 · doc4.xml · nonDerivative · entry 1

Corvese Brian · CIK 0001393207 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 307,348

F1 · price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Common Stock for each RSU. The RSUs were received in lieu of cash retainers for board and committee compensation. The RSUs will vest one month from the grant date.

SEC source: 0000899243-23-006913 · doc4.xml · nonDerivative · entry 1

Ryan Barbara · CIK 0001827169 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,844

F1 · price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Common Stock for each RSU. The RSUs were received in lieu of cash retainers for board and committee compensation. The RSUs will vest one month from the grant date.

SEC source: 0000899243-23-001964 · doc4.xml · derivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 200,000

Underlying: Common Stock · 200,000 shares

Expires 2033-01-16

F1 · derivative.exercise_date: An option to purchase Common Stock was awarded to Dr. Armen for his service as MiNK Therapeutic Inc.'s Chairman of the Board. The option was granted on January 16, 2023 and was awarded in accordance with the MiNK Therapeutics, Inc. 2021 Equity Incentive Plan. The option will vest on January 16, 2024.

SEC source: 0000899243-23-001622 · doc4.xml · derivative · entry 1

van Dijk Marcus Antonius · CIK 0001881659 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2033-01-09

F1 · derivative.exercise_date: Option was granted on January 9, 2023 and awarded in accordance with the MiNK Therapeutics, Inc. 2021 Equity Incentive Plan. Option vests over a three-year period, with one-third of the options vesting on the one-year anniversary of the grant date, with the remainder vesting in equal quarterly installments thereafter.

SEC source: 0000899243-23-001620 · doc4.xml · derivative · entry 2

Buell Jennifer · CIK 0001711184 · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 500,000

Underlying: Common Stock · 500,000 shares

Expires 2033-01-09

F3 · derivative.exercise_date: Option was granted on January 9, 2023 and awarded in accordance with the MiNK Therapeutics, Inc. 2021 Equity Incentive Plan. Option vests over a three-year period, with one-third of the options vesting on the one-year anniversary of the grant date, with the remainder vesting in equal quarterly installments thereafter.

SEC source: 0000899243-23-001620 · doc4.xml · nonDerivative · entry 1

Buell Jennifer · CIK 0001711184 · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 380,715

F1 · security: Reflects the executive's 2022 performance bonus award paid in MiNK Therapeutics, Inc. common stock. The stock issued is fully-vested on the date of issuance but is subject to a lockup restriction with 50% of the award released on March 24, 2023 and 50% of the award released on June 24, 2023.

F2 · price: $2.32 was the fair market value of MiNK Therapeutics, Inc. Common Stock on January 9, 2023, the stock issuance date.

SEC source: 0000899243-23-001660 · doc4.xml · nonDerivative · entry 2

van Dijk Marcus Antonius · CIK 0001881659 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,363

F3 · price: Represents payment of tax liability by withholding shares of common stock incident to the vesting of stock.

SEC source: 0000899243-23-001660 · doc4.xml · nonDerivative · entry 1

van Dijk Marcus Antonius · CIK 0001881659 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 51,628

F1 · security: Reflects the executive's 2022 performance bonus award paid in MiNK Therapeutics, Inc. common stock. The stock issued is fully-vested on the date of issuance but is subject to a lockup restriction with 50% of the award released on March 24, 2023 and 50% of the award released on June 24, 2023.

F2 · price: $2.32 was the fair market value of MiNK Therapeutics, Inc. Common Stock on January 9, 2023, the stock issuance date.

SEC source: 0000899243-22-037655 · doc4.xml · nonDerivative · entry 1

Baldoni John · CIK 0001851248 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,482

F1 · price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Common Stock for each RSU. The RSUs were received in lieu of cash retainers for board and committee compensation. The RSUs will vest one month from the grant date.

SEC source: 0000899243-22-037646 · doc4.xml · nonDerivative · entry 1

Behner Peter · CIK 0001851420 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,628

F1 · price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Common Stock for each RSU. The RSUs were received in lieu of cash retainers for board and committee compensation. The RSUs will vest one month from the grant date.

SEC source: 0000899243-22-037698 · doc4.xml · nonDerivative · entry 1

WIINBERG ULF · CIK 0001187314 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 36,052

F1 · price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Common Stock for each RSU. The RSUs were received in lieu of cash retainers for board and committee compensation. The RSUs will vest one month from the grant date.

F2 · balance_after: Includes shares inadvertently excluded from a Form 4 filed on September 19, 2022.

SEC source: 0000899243-22-037653 · doc4.xml · nonDerivative · entry 1

Corvese Brian · CIK 0001393207 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 298,795

F1 · price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Common Stock for each RSU. The RSUs were received in lieu of cash retainers for board and committee compensation. The RSUs will vest one month from the grant date.

F2 · balance_after: Amount owned includes 278,300 shares that were inadvertently excluded from a Form 4 filed on September 19, 2022.

SEC source: 0000899243-22-037650 · doc4.xml · nonDerivative · entry 1

Ryan Barbara · CIK 0001827169 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,351

F1 · price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Common Stock for each RSU. The RSUs were received in lieu of cash retainers for board and committee compensation. The RSUs will vest one month from the grant date.

SEC source: 0000899243-22-031534 · doc4.xml · nonDerivative · entry 1

Baldoni John · CIK 0001851248 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,974

F1 · price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Common Stock for each RSU. The RSUs were received in lieu of cash retainers for board and committee compensation. The RSUs will vest one month from the grant date.

SEC source: 0000899243-22-031530 · doc4.xml · nonDerivative · entry 1

Behner Peter · CIK 0001851420 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,737

F1 · price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Common Stock for each RSU. The RSUs were received in lieu of cash retainers for board and committee compensation. The RSUs will vest one month from the grant date.

SEC source: 0000899243-22-031528 · doc4.xml · nonDerivative · entry 1

WIINBERG ULF · CIK 0001187314 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,688

F1 · price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Common Stock for each RSU. The RSUs were received in lieu of cash retainers for board and committee compensation. The RSUs will vest one month from the grant date.

SEC source: 0000899243-22-031523 · doc4.xml · nonDerivative · entry 1

Corvese Brian · CIK 0001393207 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,646

F1 · price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Common Stock for each RSU. The RSUs were received in lieu of cash retainers for board and committee compensation. The RSUs will vest one month from the grant date.

SEC source: 0000899243-22-031529 · doc4.xml · nonDerivative · entry 1

Ryan Barbara · CIK 0001827169 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,550

F1 · price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Common Stock for each RSU. The RSUs were received in lieu of cash retainers for board and committee compensation. The RSUs will vest one month from the grant date.

SEC source: 0000899243-22-026460 · doc4.xml · nonDerivative · entry 2

WIINBERG ULF · CIK 0001187314 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 298,300

F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $1.37 - $1.51. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price.